Sihuan Pharmaceutical Holdings Group Ltd. Announces Inclusion of Xuanzhu Biopharm Shares in Hong Kong Stock Connect

Key Points for Investors

• Inclusion in Hong Kong Stock Connect: Xuanzhu Biopharmaceutical Co., Ltd., a non-wholly-owned subsidiary of Sihuan Pharmaceutical Holdings Group Ltd., has been added to the list of eligible stocks for trading under both the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect, effective from 9 March 2026.
• Potential Shareholder Impact: This inclusion opens up Xuanzhu Biopharm shares to a wider base of investors from both Hong Kong and mainland China, which is expected to significantly increase liquidity and broaden the shareholder base.
• Revaluation Opportunity: Sihuan Pharmaceutical stands to benefit from the potential revaluation of Xuanzhu Biopharm’s shares, as increased market activity and improved performance could unlock substantial value for the Group.
• Strategic Growth: The Group’s focus on innovative drugs and its dual R&D platforms position it well for future growth, especially in areas of significant unmet clinical needs.

Detailed Analysis

Sihuan Pharmaceutical Holdings Group Ltd., a leading pharmaceutical and medical aesthetics company listed in Hong Kong since 2010, has announced a major development for its business and shareholders. The Group revealed that its subsidiary, Xuanzhu Biopharmaceutical Co., Ltd., will be included in the Hong Kong Stock Connect program, following notices issued by both the Shanghai and Shenzhen Stock Exchanges on 6 March 2026. Trading access for Xuanzhu Biopharm shares through Stock Connect will commence on 9 March 2026.

What is Stock Connect and Why is it Significant?
The Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect are mechanisms that allow investors in mainland China and Hong Kong to trade eligible shares across the respective markets. Inclusion in these programs is a critical milestone as it brings new investor groups, enhances liquidity, and typically results in greater visibility and market valuation for eligible companies.

Implications for Shareholders:
The Board of Sihuan Pharmaceutical believes this development will expand Xuanzhu Biopharm’s shareholder base and improve trading liquidity. This increased accessibility to mainland and Hong Kong investors could drive up trading volumes and positively impact the share price. Furthermore, the market may revalue Xuanzhu Biopharm, which would directly benefit Sihuan Pharmaceutical as the parent company, potentially reflecting positively in Sihuan’s own share price and market performance. This news is highly relevant for investors and could be considered price sensitive.

About Xuanzhu Biopharm:
Xuanzhu Biopharm is recognized as an innovative pharmaceutical company rooted in China but with a global perspective. The company specializes in major disease areas such as digestion, oncology, and non-alcoholic steatohepatitis. Xuanzhu Biopharm is committed to the R&D, production, and commercialization of class 1 drugs with proprietary intellectual property. The company operates two advanced R&D platforms – small molecule chemistry and large molecule biopharmaceuticals – which drive its innovation. Its product pipeline spans small molecules, biopharmaceuticals, antibody-drug conjugates (ADC), and other advanced therapies, targeting unmet clinical needs and aiming to build a world-class innovative pharmaceutical company.

About Sihuan Pharmaceutical:
Founded in 2001, Sihuan Pharmaceutical has established itself as an international leader in medical aesthetics and pharmaceuticals, with a strong focus on innovation. The company boasts a robust global product pipeline, advanced R&D technology, efficient production platforms, and a mature sales system. Sihuan’s strategic goal is centered on a “two-wheel drive” strategy, promoting both medical aesthetics and biopharmaceutical businesses to position itself as a leading company in China.

Leadership and Management:
The announcement was issued by Dr. Che Fengsheng, Chairman and Executive Director, with other executive directors including Dr. Guo Weicheng (Deputy Chairman and CEO), Dr. Zhang Jionglong, Ms. Chen Yanling, and Ms. Miao Guili. Independent non-executive directors are Mr. Tsang Wah Kwong, Dr. Zhu Xun, and Mr. Wang Guan. This reflects a strong management and governance structure.

Why This News May Move the Share Price

• Market Access: Inclusion in Stock Connect increases access to mainland China investors, which could result in higher trading volumes and improved liquidity.
• Potential Revaluation: Greater market visibility may lead to a revaluation of Xuanzhu Biopharm, benefiting Sihuan Pharmaceutical’s overall valuation.
• Strategic Growth: The focus on innovative drugs and expansion in major disease areas bodes well for future revenues and profitability.
• Investor Confidence: Such developments often boost investor confidence, leading to positive momentum in share prices.

Disclaimer

This article is intended for informational purposes only and does not constitute investment advice or an offer to buy or sell any securities. Investors should conduct their own research and consult professional advisers before making investment decisions. The information herein is based on official announcements and may be subject to change.

View SIHUAN PHARM Historical chart here